Targets › SEMA4D
1 program from 1 company in 3 trials: 3 Phase 1; Oncology; next expected readout Dec 2028.
Cell surface receptor for PLXNB1 and PLXNB2 that plays an important role in cell-cell signaling. Regulates GABAergic synapse development (By similarity). (UniProt, Q92854)
Open in Phaseline: the race on SEMA4D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vaccinex | Pepinemab Semaphorin-4D inhibitor | SEMA4D | Phase 1 | Metastatic Pancreatic Adenocarcinoma; Squamous Cell Carcinoma of the Head and Neck; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Dec 2028 |
Metastatic Pancreatic Adenocarcinoma (1) Squamous Cell Carcinoma of the Head and Neck (1) Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.